Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases

Toxicology and Applied Pharmacology

Volumn 237, Issue 1, 2009, Pages 69-82

  Huang, Tien Yu ^a,b   Chu, Heng Cheng ^b   Lin, Yi Ling ^c   Lin, Chih Kung ^b   Hsieh, Tsai Yuan ^b   Chang, Wei Kuo ^b   Chao, You Chen ^d   Liao, Ching Len ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Colitis; Dextran sulfate sodium; Inducible nitric oxide synthase; Inflammatory bowel diseases; Matrix metalloproteinases; Minocycline; Trinitrobenzene sulfonic acid

Indexed keywords

ANTIBIOTIC AGENT; COLLAGENASE 3; DEXTRAN SULFATE; GELATINASE A; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; MATRIX METALLOPROTEINASE; MESSENGER RNA; MINOCYCLINE; NITRIC OXIDE; STROMELYSIN; TRINITROBENZENESULFONIC ACID;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC DISEASE; COLITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; ENTERITIS; EXPERIMENTAL MODEL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INTESTINE CELL; MALE; MORTALITY; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; COLITIS; CYTOKINES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; INFLAMMATION; MALE; MATRIX METALLOPROTEINASES; METRONIDAZOLE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MINOCYCLINE; NITRIC OXIDE SYNTHASE TYPE II; RNA, MESSENGER; SPECIES SPECIFICITY; SURVIVAL ANALYSIS; TRINITROBENZENESULFONIC ACID;

MUS;

EID: 67349085738     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.02.026     Document Type: Article

References (78)

1. Amin A.R., Attur M.G., Thakker G.D., Patel P.D., Vyas P.R., Patel R.N., Patel I.R., and Abramson S.B. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 14014-14019
2. Amin A.R., Patel R.N., Thakker G.D., Lowenstein C.J., Attur M.G., and Abramson S.B. Post-transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines. FEBS Lett. 410 (1997) 259-264
3. Archer S. Measurement of nitric oxide in biological models. Faseb. J. 7 (1993) 349-360
4. Barrie A., and Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm. Bowel Dis. 13 (2007) 1424-1429
5. Baugh M.D., Perry M.J., Hollander A.P., Davies D.R., Cross S.S., Lobo A.J., Taylor C.J., and Evans G.S. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 117 (1999) 814-822
6. Beck P.L., Xavier R., Wong J., Ezedi I., Mashimo H., Mizoguchi A., Mizoguchi E., Bhan A.K., and Podolsky D.K. Paradoxical roles of different nitric oxide synthase isoforms in colonic injury. Am. J. Physiol. Gastrointest. Liver Physiol. 286 (2004) G137-147
7. Boughton-Smith N.K. Pathological and therapeutic implications for nitric oxide in inflammatory bowel disease. J. R. Soc. Med. 87 (1994) 312-314
8. Bouma G., and Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3 (2003) 521-533
9. Bradley P.P., Priebat D.A., Christensen R.D., and Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J. Invest. Dermatol. 78 (1982) 206-209
10. Castaneda F.E., Walia B., Vijay-Kumar M., Patel N.R., Roser S., Kolachala V.L., Rojas M., Wang L., Oprea G., Garg P., Gewirtz A.T., Roman J., Merlin D., and Sitaraman S.V. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology 129 (2005) 1991-2008
11. Chen M., Ona V.O., Li M., Ferrante R.J., Fink K.B., Zhu S., Bian J., Guo L., Farrell L.A., Hersch S.M., Hobbs W., Vonsattel J.P., Cha J.H., and Friedlander R.M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6 (2000) 797-801
12. Chu H.C., Lin Y.L., Sytwu H.K., Lin S.H., Liao C.L., and Chao Y.C. Effects of minocycline on Fas-mediated fulminant hepatitis in mice. Br. J. Pharmacol. 144 (2005) 275-282
13. Cooper H.S., Murthy S.N., Shah R.S., and Sedergran D.J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 69 (1993) 238-249
14. Corry D.B., Rishi K., Kanellis J., Kiss A., Song Lz L.Z., Xu J., Feng L., Werb Z., and Kheradmand F. Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency. Nat. Immunol. 3 (2002) 347-353
15. Cross R.K., and Wilson K.T. Nitric oxide in inflammatory bowel disease. Inflamm. Bowel Dis. 9 (2003) 179-189
16. Danese S., Sans M., de la Motte C., Graziani C., West G., Phillips M.H., Pola R., Rutella S., Willis J., Gasbarrini A., and Fiocchi C. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 130 (2006) 2060-2073
17. Dieleman L.A., Ridwan B.U., Tennyson G.S., Beagley K.W., Bucy R.P., and Elson C.O. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107 (1994) 1643-1652
18. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., Triarhou L.C., Chernet E., Perry K.W., Nelson D.L., Luecke S., Phebus L.A., Bymaster F.P., and Paul S.M. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 14669-14674
19. Dubois B., Starckx S., Pagenstecher A., Oord J., Arnold B., and Opdenakker G. Gelatinase B deficiency protects against endotoxin shock. Eur. J. Immunol. 32 (2002) 2163-2171
20. Elson C.O., Sartor R.B., Tennyson G.S., and Riddell R.H. Experimental models of inflammatory bowel disease. Gastroenterology 109 (1995) 1344-1367
21. Elson C.O., Beagley K.W., Sharmanov A.T., Fujihashi K., Kiyono H., Tennyson G.S., Cong Y., Black C.A., Ridwan B.W., and McGhee J.R. Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. J. Immunol. 157 (1996) 2174-2185
22. Gionchetti P., Rizzello F., Lammers K.M., Morselli C., Tambasco R., and Campieri M. Antimicrobials in the management of inflammatory bowel disease. Digestion 73 Suppl. 1 (2006) 77-85
23. Hautamaki R.D., Kobayashi D.K., Senior R.M., and Shapiro S.D. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 277 (1997) 2002-2004
24. Hokari R., Kato S., Matsuzaki K., Kuroki M., Iwai A., Kawaguchi A., Nagao S., Miyahara T., Itoh K., Sekizuka E., Nagata H., Ishii H., and Miura S. Reduced sensitivity of inducible nitric oxide synthase-deficient mice to chronic colitis. Free Radic. Biol. Med. 31 (2001) 153-163
25. Hu J., Van den Steen P.E., Sang Q.X., and Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 6 (2007) 480-498
26. Kankuri E., Vaali K., Knowles R.G., Lahde M., Korpela R., Vapaatalo H., and Moilanen E. Suppression of acute experimental colitis by a highly selective inducible nitric-oxide synthase inhibitor, N-[3-(aminomethyl)benzyl]acetamidine. J. Pharmacol. Exp. Ther. 298 (2001) 1128-1132
27. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., Siegel J.N., and Braun M.M. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345 (2001) 1098-1104
28. Kielian T., Esen N., Liu S., Phulwani N.K., Syed M.M., Phillips N., Nishina K., Cheung A.L., Schwartzman J.D., and Ruhe J.J. Minocycline modulates neuroinflammation independently of its antimicrobial activity in Staphylococcus aureus-induced brain abscess. Am. J. Pathol. 171 (2007) 1199-1214
29. Kirkegaard T., Hansen A., Bruun E., and Brynskov J. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut 53 (2004) 701-709
30. Kloppenburg M., Verweij C.L., Miltenburg A.M., Verhoeven A.J., Daha M.R., Dijkmans B.A., and Breedveld F.C. The influence of tetracyclines on T cell activation. Clin. Exp. Immunol. 102 (1995) 635-641
31. Koistinaho M., Malm T.M., Kettunen M.I., Goldsteins G., Starckx S., Kauppinen R.A., Opdenakker G., and Koistinaho J. Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. J. Cereb. Blood Flow Metab. 25 (2005) 460-467
32. Korzenik J.R., and Podolsky D.K. Evolving knowledge and therapy of inflammatory bowel disease. Nat. Rev. Drug Discov. 5 (2006) 197-209
33. Krieglstein C.F., Cerwinka W.H., Laroux F.S., Salter J.W., Russell J.M., Schuermann G., Grisham M.B., Ross C.R., and Granger D.N. Regulation of murine intestinal inflammation by reactive metabolites of oxygen and nitrogen: divergent roles of superoxide and nitric oxide. J. Exp. Med. 194 (2001) 1207-1218
34. Lee C.Z., Yao J.S., Huang Y., Zhai W., Liu W., Guglielmo B.J., Lin E., Yang G.Y., and Young W.L. Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J. Cereb. Blood Flow Metab. 26 (2006) 1157-1164
35. Macdonald T.T., and Monteleone G. Immunity, inflammation, and allergy in the gut. Science 307 (2005) 1920-1925
36. Machado L.S., Kozak A., Ergul A., Hess D.C., Borlongan C.V., and Fagan S.C. Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci. 7 (2006) 56
37. Mahler M., Bristol I.J., Leiter E.H., Workman A.E., Birkenmeier E.H., Elson C.O., and Sundberg J.P. Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis. Am. J. Physiol. 274 (1998) G544-551
38. Martinez J.A., Williams C.S., Amann J.M., Ellis T.C., Moreno-Miralles I., Washington M.K., Gregoli P., and Hiebert S.W. Deletion of Mtgr1 sensitizes the colonic epithelium to dextran sodium sulfate-induced colitis. Gastroenterology 131 (2006) 579-588
39. Medina C., and Radomski M.W. Role of matrix metalloproteinases in intestinal inflammation. J. Pharmacol. Exp. Ther. 318 (2006) 933-938
40. Medina C., Videla S., Radomski A., Radomski M.W., Antolin M., Guarner F., Vilaseca J., Salas A., and Malagelada J.R. Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 284 (2003) G116-122
41. Medina C., Santana A., Paz M.C., Diaz-Gonzalez F., Farre E., Salas A., Radomski M.W., and Quintero E. Matrix metalloproteinase-9 modulates intestinal injury in rats with transmural colitis. J. Leukoc. Biol. 79 (2006) 954-962
42. Meijer M.J., Mieremet-Ooms M.A., van der Zon A.M., van Duijn W., van Hogezand R.A., Sier C.F., Hommes D.W., Lamers C.B., and Verspaget H.W. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig. Liver Dis. 39 (2007) 733-739
43. Menchen L.A., Colon A.L., Moro M.A., Leza J.C., Lizasoain I., Menchen P., Alvarez E., and Lorenzo P. N-(3-(aminomethyl)benzyl)acetamidine, an inducible nitric oxide synthase inhibitor, decreases colonic inflammation induced by trinitrobenzene sulphonic acid in rats. Life Sci. 69 (2001) 479-491
44. Morris G.P., Beck P.L., Herridge M.S., Depew W.T., Szewczuk M.R., and Wallace J.L. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96 (1989) 795-803
45. Muller-Pillasch F., Gress T.M., Yamaguchi H., Geng M., Adler G., and Menke A. The influence of transforming growth factor beta 1 on the expression of genes coding for matrix metalloproteinases and tissue inhibitors of metalloproteinases during regeneration from cerulein-induced pancreatitis. Pancreas 15 (1997) 168-175
46. Munkholm P., Langholz E., Davidsen M., and Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 35 (1994) 360-362
47. Naito Y., and Yoshikawa T. Role of matrix metalloproteinases in inflammatory bowel disease. Mol. Aspects Med. 26 (2005) 379-390
48. Naito Y., Takagi T., Kuroda M., Katada K., Ichikawa H., Kokura S., Yoshida N., Okanoue T., and Yoshikawa T. An orally active matrix metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium-induced colitis in mice. Inflamm. Res. 53 (2004) 462-468
49. Obermeier F., Kojouharoff G., Hans W., Scholmerich J., Gross V., and Falk W. Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin. Exp. Immunol. 116 (1999) 238-245
50. Ohkawara T., Nishihira J., Takeda H., Hige S., Kato M., Sugiyama T., Iwanaga T., Nakamura H., Mizue Y., and Asaka M. Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice. Gastroenterology 123 (2002) 256-270
51. Okayasu I., Hatakeyama S., Yamada M., Ohkusa T., Inagaki Y., and Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98 (1990) 694-702
52. Onderdonk A.B., Hermos J.A., Dzink J.L., and Bartlett J.G. Protective effect of metronidazole in experimental ulcerative colitis. Gastroenterology 74 (1978) 521-526
53. Opdenakker G., Nelissen I., and Van Damme J. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol. 2 (2003) 747-756
54. Rath H.C., Schultz M., Freitag R., Dieleman L.A., Li F., Linde H.J., Scholmerich J., and Sartor R.B. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect. Immun. 69 (2001) 2277-2285
55. Rifkin B.R., Vernillo A.T., and Golub L.M. Blocking periodontal disease progression by inhibiting tissue-destructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs. J. Periodontol. 64 (1993) 819-827
56. Sadlack B., Merz H., Schorle H., Schimpl A., Feller A.C., and Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75 (1993) 253-261
57. Sapadin A.N., and Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J. Am. Acad. Dermatol. 54 (2006) 258-265
58. Sartor R.B. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126 (2004) 1620-1633
59. Sellon R.K., Tonkonogy S., Schultz M., Dieleman L.A., Grenther W., Balish E., Rennick D.M., and Sartor R.B. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect. Immun. 66 (1998) 5224-5231
60. Shenefelt P.D. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen. Cutis 57 (1996) 315-319
61. Sorsa T., Tjaderhane L., Konttinen Y.T., Lauhio A., Salo T., Lee H.M., Golub L.M., Brown D.L., and Mantyla P. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann. Med. 38 (2006) 306-321
62. Sriram K., Miller D.B., and O'Callaghan J.P. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J. Neurochem. 96 (2006) 706-718
63. Stone M., Fortin P.R., Pacheco-Tena C., and Inman R.D. Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. J. Rheumatol. 30 (2003) 2112-2122
64. Sutton T.A., Kelly K.J., Mang H.E., Plotkin Z., Sandoval R.M., and Dagher P.C. Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. Am. J. Physiol. Renal. Physiol. 288 (2005) F91-97
65. Tamaki H., Nakamura H., Nishio A., Nakase H., Ueno S., Uza N., Kido M., Inoue S., Mikami S., Asada M., Kiriya K., Kitamura H., Ohashi S., Fukui T., Kawasaki K., Matsuura M., Ishii Y., Okazaki K., Yodoi J., and Chiba T. Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production. Gastroenterology 131 (2006) 1110-1121
66. Tamargo R.J., Bok R.A., and Brem H. Angiogenesis inhibition by minocycline. Cancer Res. 51 (1991) 672-675
67. Tessner T.G., Cohn S.M., Schloemann S., and Stenson W.F. Prostaglandins prevent decreased epithelial cell proliferation associated with dextran sodium sulfate injury in mice. Gastroenterology 115 (1998) 874-882
68. Thomas M., Ashizawa T., and Jankovic J. Minocycline in Huntington's disease: a pilot study. Mov. Disord. 19 (2004) 692-695
69. Truelove S.C., and Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br. Med. J. 2 (1955) 1041-1048
70. Van den Steen P.E., Proost P., Grillet B., Brand D.D., Kang A.H., Van Damme J., and Opdenakker G. Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis. Faseb J. 16 (2002) 379-389
71. Van Lint P., Wielockx B., Puimege L., Noel A., Lopez-Otin C., and Libert C. Resistance of collagenase-2 (matrix metalloproteinase-8)-deficient mice to TNF-induced lethal hepatitis. J. Immunol. 175 (2005) 7642-7649
72. Vizoso F.J., Gonzalez L.O., Corte M.D., Corte M.G., Bongera M., Martinez A., Martin A., Andicoechea A., and Gava R.R. Collagenase-3 (MMP-13) expression by inflamed mucosa in inflammatory bowel disease. Scand. J. Gastroenterol. 41 (2006) 1050-1055
73. Warris A., Bjorneklett A., and Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N. Engl. J. Med. 344 (2001) 1099-1100
74. Williams K.L., Fuller C.R., Dieleman L.A., DaCosta C.M., Haldeman K.M., Sartor R.B., and Lund P.K. Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology 120 (2001) 925-937
75. Wirtz S., and Neurath M.F. Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease. Int. J. Colorectal Dis. 15 (2000) 144-160
76. Yue G., Lai P.S., Yin K., Sun F.F., Nagele R.G., Liu X., Linask K.K., Wang C., Lin K.T., and Wong P.Y. Colon epithelial cell death in 2,4,6-trinitrobenzenesulfonic acid-induced colitis is associated with increased inducible nitric-oxide synthase expression and peroxynitrite production. J. Pharmacol. Exp. Ther. 297 (2001) 915-925
77. Zhu S., Stavrovskaya I.G., Drozda M., Kim B.Y., Ona V., Li M., Sarang S., Liu A.S., Hartley D.M., Wu du C., Gullans S., Ferrante R.J., Przedborski S., Kristal B.S., and Friedlander R.M. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417 (2002) 74-78
78. Zingarelli B., Szabo C., and Salzman A.L. Reduced oxidative and nitrosative damage in murine experimental colitis in the absence of inducible nitric oxide synthase. Gut 45 (1999) 199-209